Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 18/20 | 0.63 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.63 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.63 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.63 |
| ▸ | F10 | P00742 | 2/20 | 0.63 |
| ▸ | PLAT | P00750 | 1/20 | 0.63 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23460615 | 0.90 | F2 (0.61) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6850252 | 0.90 | F2 (0.56) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL4904924 | 0.88 | F2 (0.67) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL14281097 | 0.87 | F2 (0.68) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6957416 | 0.87 | F2 (0.70) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL23460833 | 0.84 | F2 (0.48) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5474694 | 0.82 | F2 (0.64) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL23461135 | 0.82 | F2 (0.48) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL7448903 | 0.80 | F2 (0.60) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6846360 | 0.80 | F2 (0.58) | F2PRSS1PRSS2PRSS3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | PATEL MITUL N | 2008-01-24 | — | — | US | disclosed |
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | PATEL MITUL N | 2008-01-24 | — | — | US | disclosed |
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | PATEL MITUL N | 2008-01-24 | — | — | US | disclosed |
| WO-2007146553-A2 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146553-A2 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-12-21 | — | — | WO | disclosed |
| US-7030110-B2 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6476016-B2 | INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, INHIBITING THROMBUS FORMATION, AND INHIBITING EMBOLUS FORMATION | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6011038-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | F2 12/4885PRSS1 15/4885PRSS2 21/4885 |
| US-20080021044-A1 | N-[2-[[(DIAMINOMETHYLENE)AMINO]OXY]ETHYL]-3-[(2,2-DIFLUORO-2-PHENYLETHYL)AMINO]-6-METHYL-2-OXO-1(2H)-PYRAZINEACETAMIDE | DNPEP, SPINT2, PEPD | F2 154/4885PRSS1 18/4885PRSS2 12/4885 |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | F2 12/4885PRSS1 15/4885PRSS2 21/4885 |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, TFPI, F12 | F2 9/4885PRSS1 15/4885PRSS2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.